Arihant Senthil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arihant Senthil has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Rohit Jain
Penn State Milton S. Hershey Medical Center
2 shared publications - Vasu Bansal
University of Missouri, Kansas City, Missouri
2 shared publications - Aarushi Gupta
Avalon University School of Medicine
1 shared publication Caroline Antony
M.S. Ramaiah Medical college
1 shared publication- Gunn Goel
All India Institute of Medical Sciences, Bathinda, India
1 shared publication Himanshi Banker
Tucson Medical Center, United States of America, Tucson, USA
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 8, 121-136
Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies
Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.
- 29 July 2026
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 8, 121-136
Open AccessAdvances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies
Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.
- 23 July 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 327
Obstructive Sleep Apnea as a Potentially Modifiable Risk Factor in Neurodegeneration: Mechanisms, Evidence, and Clinical Implications
- 23 July 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 327
Obstructive Sleep Apnea as a Potentially Modifiable Risk Factor in Neurodegeneration: Mechanisms, Evidence, and Clinical Implications
- 11 July 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (6) , 665-675
Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety
Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) are BCR:ABL1-driven hematologic malignancies that account for a substantial proportion of ...
- 11 July 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (6) , 665-675
Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety
Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) are BCR:ABL1-driven hematologic malignancies that account for a substantial proportion of ...